ENDRA Life Sciences (NDRA) Convertible Debt (2018)
ENDRA Life Sciences (NDRA) posted quarterly Convertible Debt of $681187.0 for Q3 2018, up 92.65% quarter-over-quarter from $353581.0 in Q2 2018.
ENDRA Life Sciences (NDRA) Convertible Debt (2018) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Convertible Debt for 1 consecutive years, with $681187.0 the latest figure, recorded in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn |
| 10 | ENDRA Life Sciences | 7.16 Mn | 1.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 681,187.00 |
| Jun 30, 2018 | 353,581.00 |